AI in healthcare market seen topping $91 billion by 2030

The Business Research Company says the artificial intelligence in healthcare market is on track to surpass $91 billion by 2030, with North America and the U.S. driving much of the growth. The report also highlights hardware as the biggest segment and Nvidia as the leading global seller in 2025.

Why it matters: - AI is moving from pilot projects to core healthcare infrastructure across diagnostics, workflow automation, drug discovery and patient monitoring. - The market’s projected scale points to a major spending shift across hospitals, insurers, drugmakers and health tech vendors. - Hardware, software and services are all expected to benefit as healthcare systems build out AI-ready infrastructure.

What happened: - The Business Research Company released its Competitive Landscape of the Artificial Intelligence in Healthcare Global Market Report 2026. - The report projects the artificial intelligence in healthcare market will exceed $91 billion by 2030. - North America is forecast to be the largest regional market by 2030 at $53 billion. - The U.S. is expected to be the biggest single-country market by 2030 at $47 billion. - Nvidia Corporation led global sales in 2025 with a 14% share.

The details: - The market is forecast to grow from $13 billion in North America in 2025 to $53 billion in 2030, a 33% CAGR. - The U.S. market is projected to rise from $12 billion in 2025 to $47 billion in 2030, a 32% CAGR. - The broader AI market is expected to reach about $920 billion by 2030, putting healthcare AI at about 10% of that total. - The information technology market is projected to reach $13,788 billion in 2030, with healthcare AI at nearly 1% of that value. - Hardware is expected to be the largest offering segment by 2030, accounting for 56% of the market, or $51 billion. - Between 2025 and 2030, hardware is projected to grow by $37 billion, software by $18 billion and services by $12 billion. - The report says the hardware segment is being supported by AI-optimized medical edge devices, GPUs, AI accelerators, smart diagnostic imaging systems, IoT-based monitoring and hospital data center expansion. - The market spans deep learning, querying methods, natural language processing and context-aware processing. - Application areas include robot-assisted surgery, virtual nursing assistants, administrative workflow assistance, fraud detection, dosage error reduction, clinical trial participant identification and preliminary diagnosis. - Key end users include hospitals, diagnostic centers, pharmaceutical and biopharmaceutical companies, healthcare payers and patients. - The report identifies precision medicine, early disease detection and healthcare data digitization as major growth drivers. - Precision medicine adoption is estimated to add 3.0% annual growth. - Early disease detection is estimated to add 2.8% annual growth. - Healthcare data digitization is estimated to add 2.5% annual growth. - The most promising growth opportunities are in hardware, software and services, which are expected to contribute more than $67 billion combined by 2030. - The market’s competitive environment is described as moderately fragmented, with the top 10 companies accounting for 23% of revenue in 2025. - The report says competitive factors include data security, regulatory compliance, interoperability and clinical workflow integration. - Prominent companies named in the report include Nvidia Corporation, Alphabet Inc., IQVIA Inc., Nuance Communications, Ping An Health Medical Technology, Recursion Pharmaceuticals, OWKIN, PathAI, BenevolentAI, Atomwise, Deep Genomics, Iktos, Berg LLC, Cambridge Cognition, Lybrate, Rology, Insilico, Botkin, Cloud Pharmaceuticals, Gero, Artelus, Skin Analytics, Nucleai, Ardigen, Envisagenics, Diagnocat and Oncora Medical. - The report also lists raw material and technology suppliers including NVIDIA, Intel, AMD, Qualcomm, IBM, Microsoft, Google, Amazon Web Services, Oracle, Dell, Hewlett Packard Enterprise, Cisco, Samsung, Micron, Broadcom, Arm, Lenovo, Super Micro Computer, Pure Storage, Snowflake, Databricks, Palantir, ServiceNow and Red Hat. - Distribution partners named in the report include Arrow Electronics, Avnet, Digi-Key, Mouser Electronics, Future Electronics, RS Group, Newark, TTI, Allied Electronics & Automation, Ingram Micro, TD SYNNEX, CDW, Insight Enterprises, SHI International, Softchoice, Bechtle, ALSO, Esprinet, ScanSource, Exclusive Networks, Westcon Group, Redington, Mindware, ASBIS and Logicom. - End users listed include GE HealthCare Technologies, Siemens Healthineers, Philips, Medtronic, Johnson & Johnson, Roche, AstraZeneca, Pfizer, Novartis, Bristol Myers Squibb, Merck, Eli Lilly, Abbott, Thermo Fisher Scientific, Mayo Clinic, Cleveland Clinic, Johns Hopkins Medicine, Massachusetts General Hospital, HCA Healthcare, Kaiser Permanente, UnitedHealth Group, Elevance Health, CVS Health, Quest Diagnostics and Laboratory Corporation of America.

Between the lines: - The report suggests healthcare AI is shifting from software-led experimentation toward infrastructure-heavy deployment, with hardware now a central spending category. - The emphasis on compliance and interoperability shows that adoption depends as much on regulation and integration as on model performance. - Oracle’s AI-driven EHR rollout in August 2025 signals that large enterprise vendors are pushing deeper into clinical workflow automation.

What's next: - The report expects continued expansion through 2030 as AI adoption spreads across clinical decision support, imaging, precision medicine and healthcare operations. - Vendors are likely to compete on diagnostic accuracy, workflow integration, data security and partnerships with healthcare organizations. - The company says future market reports will include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated graphics and tables.

The bottom line: - Healthcare AI is emerging as a large, fast-growing market with the U.S. and North America in the lead and hardware taking an outsized share of future spending.